Impact of Cancer Type and Treatment Timing on the Benefit of Comprehensive Genome Profiling–Based Precision Oncology
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology
ESMO Open 2024 Apr 12;9(4)102981, T Kubo, K Sunami, T Koyama, M Kitami, Y Fujiwara, S Kondo, K Yonemori, E Noguchi, C Morizane, Y Goto, A Maejima, S Iwasa, T Hamaguchi, A Kawai, K Namikawa, A Arakawa, M Sugiyama, M Ohno, T Yoshida, N Hiraoka, A Yoshida, M Yoshida, T Nishino, E Furukawa, D Narushima, M Nagai, M Kato, H Ichikawa, Y Fujiwara, T Kohno, N YamamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.